Optimal duration of adjuvant bisphosphonate treatment for high-risk early breast cancer: Results from a SUCCESS trial
Thorac Cancer
.
2022 Feb;13(3):519-520.
doi: 10.1111/1759-7714.14257.
Epub 2022 Jan 2.
Authors
Mingbei Lu
1
,
Beibei Ren
1
,
Lingyan Rao
1
Affiliation
1
Department of Thyroid and Breast Surgery, Lishui People's Hospital, Lishui, China.
PMID:
34978157
PMCID:
PMC8807267
DOI:
10.1111/1759-7714.14257
No abstract available
Keywords:
SUCCESS A trial; adjuvant bisphosphonate treatment; breast cancer; treatment duration.
Publication types
Letter
Comment
MeSH terms
Breast
Breast Neoplasms* / drug therapy
Chemotherapy, Adjuvant
Diphosphonates* / therapeutic use
Female
Humans
Substances
Diphosphonates